Australian biotech giant CSL said on Tuesday it plans to demerge its influenza vaccine division, CSL Seqirus, into a separately listed company by the end of the financial year 2026, alongside job cuts ...

Robert Kennedy Jr. signs recommendation eliminating mercury-based thimerosal from influenza vaccines, fulfilling anti-vaccine ...

If you are in one of 34 states, you can now order AstraZeneca's FluMist Home vaccine online to be delivered to your home ...

The FDA approved AstraZeneca’s no-prescription FluMist vaccine in September 2024. Now with FluMist Home, people can have it ...

AstraZeneca has issued its flu vaccine nasal spray for at-home use. The nasal spray is authorized for use by adults ages 18-49 and for caregiver use with children ages 2-17, according to an Aug. 15 ...

The vaccine requires a prescription, which people can obtain by filling out a medical screening questionnaire through the ...

Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and ...

HHS reinstates vaccine safety task force apparently in response to looming lawsuit deadline by group Secretary Kennedy ...

CSL also said it would restart a multi-year share buyback program from FY26, beginning with A$750 million. Chief Executive ...

Once received, the vaccine should be stored in the refrigerator until it is used. Then, people between the ages of 18 and 49 ...

CSL’s headcount reduction and vaccine spinoff dragged shares down 9.5%, from A$271.32 at market close on 18 August to ...

Australian biotech giant CSL Ltd on Tuesday announced plans to demerge its influenza vaccine division, CSL Seqirus, and said it will lay off up to 15% of its workforce, after reporting a strong growth ...